MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Hallucinations"

  • MDS Virtual Congress 2020

    Homer1 polymorphism in patients with Parkinson’s disease and psychosis

    A. Lenka, S. Vadivel, R. Christopher, S. Arumugham, S. Hegde, R. Yadav, P. Pal (Washington, DC, USA)

    Objective: To explore the association of psychosis in Parkinson’s disease with polymorphisms of HOMER1, a gene whose product (Homer1) is responsible for modulating the metabotropic…
  • MDS Virtual Congress 2020

    Increased illusory responses in non-hallucinating, cognitively impaired Lewy body disease patients

    M. Shahid, A. Rawls, V. Ramirez, S. Ryman, V. Santini, L. Yang, S. Sha, J. Hall, T. Montine, L. Tian, B. Cholerton, V. Henderson, M. Yutsis, K. Poston (Stanford, CA, USA)

    Objective: To determine whether non-hallucinating Lewy body disease-spectrum patients report increased illusory responses. Background: Pareidolias are specific illusions of faces and objects perceived in formless…
  • MDS Virtual Congress 2020

    Genetic risk scores and hallucinations in Parkinson’s disease patients

    C. Kusters, K. Paul, A. Duarte Folle, A. Keener, J. Bronstein, V. Dobricic, O.B Tysnes, L. Bertram, G. Alves, J. Sinsheimer, C. Lill, J. Maple-Grødem, B. Ritz (Los Angeles, CA, USA)

    Objective: To examine the overlap of genetic architecture for Alzheimer’s disease (AD), schizophrenia (SZ), and PD with the genetic architecture for the occurrence of hallucinations…
  • MDS Virtual Congress 2020

    Management of neuropsychiatric symptoms in Parkinson’s disease (PD) at the front door

    M.A Farooqi, A. Chatterjee (Reading, United Kingdom)

    Objective: To ascertain the number of PD patients admitted to the acute hospital with neuropsychiatric symptoms requiring a review by PD specialist, including medicine reconciliation…
  • 2019 International Congress

    Rivastigmine for visual hallucinations in Parkinson’s disease

    T. Mierlo, E. Foncke, R. Bie (Amsterdam, Netherlands)

    Objective: The aim of the study is to investigate whether early rivastigmine treatment of visual hallucinations in patients with Parkinson's disease delays the progression of…
  • 2019 International Congress

    The role of dysfunctional attentional processing in isolated minor hallucinations in Parkinson’s disease

    H. Bejr-Kasem, J. Pagonabarraga, S. Martínez-Horta, F. Ruiz-Martínez, F. Bernasconi, F. Sampedro, J. Marín-Lahoz, A. Horta-Barba, I. Aracil-Bolaños, B. Pascual-Sedano, O. Blanke, J. Kulisevsky (Barcelona, Spain)

    Objective: To explore attentional processing deficits in Parkinson's disease (PD) with minor hallucinations using a selective visual attention task. Background: Recent literature points to a…
  • 2019 International Congress

    Frequency of neuropsychiatric symptoms in non-demented early and late-onset Parkinson’s disease patients

    A. Seubert-Ravelo, MG. Yáñez-Téllez, G. Neri-Nani, X. Ortiz-Jiménez, C. Guerra-Galicia (Estado de México, Mexico)

    Objective: To compare the frequency of neuropsychiatric symptoms (NPS) (depression, anxiety, psychotic, irritability, aggression, euphoria, apathy, behavioral disinhibition, repetitive motor behavior (RMB) and eating disorder)…
  • 2019 International Congress

    Correlation between Pareidolia and cerebral perfusion by SPECT in Parkinson’s disease without dementia: A retrospective study

    H. Akamine, T. Tokashiki (Ginowan, Japan)

    Objective: The aim of this study is to investigate the correlation between the number of illusory responses on the Pareidolia test and cerebral perfusion in…
  • 2019 International Congress

    A possible case of prodromal DLB with prominent hallucinations, autonomic dysfunction, and REM behavior disorder but absence of cognitive impairment

    K. Amodeo (Rochester, NY, USA)

    Objective: Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia, after Alzheimer’s disease (AD). While mild cognitive impairment (MCI) is…
  • 2019 International Congress

    Cognitive dysfunction in patients with Parkinson’s disease and psychosis

    A. Lenka, S. Hegde, S. Arumugham, R. Yadav, P. Pal (Washington, DC, USA)

    Objective: The objective of this study was to explore the pattern of cognitive dysfunction in the patient's with Parkinson's disease and psychosis (PD-P) by comparing…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley